CN106046007B - 酪氨酸激酶抑制剂及包含该酪氨酸激酶抑制剂的药物组合物 - Google Patents

酪氨酸激酶抑制剂及包含该酪氨酸激酶抑制剂的药物组合物 Download PDF

Info

Publication number
CN106046007B
CN106046007B CN201610211659.0A CN201610211659A CN106046007B CN 106046007 B CN106046007 B CN 106046007B CN 201610211659 A CN201610211659 A CN 201610211659A CN 106046007 B CN106046007 B CN 106046007B
Authority
CN
China
Prior art keywords
compound
milligrams
alkyl
milliliters
added
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201610211659.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN106046007A (zh
Inventor
龙超峰
陈正霞
陈小新
张杨
刘卓伟
李鹏
陈曙辉
梁贵柏
谢诚
李正伟
付志飞
胡国平
黎健
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Guangdong Zhongsheng Ruichuang Biotechnology Co Ltd
Original Assignee
Guangdong Zhongsheng Ruichuang Biotechnology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Guangdong Zhongsheng Ruichuang Biotechnology Co Ltd filed Critical Guangdong Zhongsheng Ruichuang Biotechnology Co Ltd
Publication of CN106046007A publication Critical patent/CN106046007A/zh
Application granted granted Critical
Publication of CN106046007B publication Critical patent/CN106046007B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576—Six-membered rings
    • C07F9/60—Quinoline or hydrogenated quinoline ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Pyridine Compounds (AREA)
CN201610211659.0A 2015-04-07 2016-04-07 酪氨酸激酶抑制剂及包含该酪氨酸激酶抑制剂的药物组合物 Active CN106046007B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2015101616744 2015-04-07
CN201510161674 2015-04-07

Publications (2)

Publication Number Publication Date
CN106046007A CN106046007A (zh) 2016-10-26
CN106046007B true CN106046007B (zh) 2019-02-05

Family

ID=57072288

Family Applications (3)

Application Number Title Priority Date Filing Date
CN201610211659.0A Active CN106046007B (zh) 2015-04-07 2016-04-07 酪氨酸激酶抑制剂及包含该酪氨酸激酶抑制剂的药物组合物
CN201680019729.0A Active CN107683279B (zh) 2015-04-07 2016-04-07 酪氨酸激酶抑制剂及包含该酪氨酸激酶抑制剂的药物组合物
CN202011033493.0A Active CN112028825B (zh) 2015-04-07 2016-04-07 酪氨酸激酶抑制剂及包含该酪氨酸激酶抑制剂的药物组合物

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN201680019729.0A Active CN107683279B (zh) 2015-04-07 2016-04-07 酪氨酸激酶抑制剂及包含该酪氨酸激酶抑制剂的药物组合物
CN202011033493.0A Active CN112028825B (zh) 2015-04-07 2016-04-07 酪氨酸激酶抑制剂及包含该酪氨酸激酶抑制剂的药物组合物

Country Status (5)

Country Link
US (1) US10654808B2 (enExample)
EP (1) EP3293177B1 (enExample)
JP (2) JP6617155B6 (enExample)
CN (3) CN106046007B (enExample)
WO (1) WO2016161952A1 (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4023640A1 (en) * 2015-12-25 2022-07-06 Otsuka Pharmaceutical Factory, Inc. Phenylimidazole compound
EP3521276B1 (en) * 2016-09-30 2021-03-10 Guangdong Raynovent Biotech Co., Ltd. Crystal form and salt form of and preparation method for tyrosine kinase inhibitor
US10800741B2 (en) 2017-02-07 2020-10-13 Ancureall Pharmaceutical (Shanghai) Co., Ltd. Quinoline compound, preparation method and medical use therefor
CN107115344B (zh) * 2017-03-23 2019-06-14 广东众生睿创生物科技有限公司 酪氨酸激酶抑制剂在制备用于预防和/或治疗纤维化疾病的药物中的用途
KR102327054B1 (ko) * 2017-08-29 2021-11-17 기초과학연구원 퀴놀린 유도체 및 alk와 변이된 alk의 저해제로서의 용도
AU2018325445A1 (en) * 2017-08-31 2020-03-19 Abbvie Inc. Ectonucleotide pyrophosphatase-phosphodiesterase 1 (ENPP-1) inhibitors and uses thereof
WO2019062637A1 (zh) * 2017-09-28 2019-04-04 南京明德新药研发股份有限公司 喹啉衍生物及其作为酪氨酸激酶抑制剂的应用
CN108623521B (zh) * 2018-03-22 2020-09-04 盐城师范学院 一种乐伐替尼的制备方法
CN110483482A (zh) 2018-05-15 2019-11-22 北京诺诚健华医药科技有限公司 吲哚啉-1-甲酰胺类化合物、其制备方法及其在医药学上的应用
CN110590839B (zh) * 2018-06-13 2022-04-05 四川海思科制药有限公司 一种乐伐替尼衍生物及制备方法和用途
CN110862397A (zh) * 2018-08-27 2020-03-06 北京赛特明强医药科技有限公司 二噁烷并喹唑啉与二噁烷并喹啉类化合物及其制备方法与应用
EP3876939A4 (en) 2018-11-07 2022-08-10 Dana-Farber Cancer Institute, Inc. Benzothiazole derivatives and 7-aza-benzothiazole derivatives as janus kinase 2 inhibitors and uses thereof
US12509455B2 (en) 2018-11-07 2025-12-30 Dana-Farber Cancer Institute, Inc. Imidazopyridine derivatives and aza-imidazopyridine derivatives as Janus kinase 2 inhibitors and uses thereof
WO2020097396A1 (en) 2018-11-07 2020-05-14 Dana-Farber Cancer Institute, Inc. Benzimidazole derivatives and aza-benzimidazole derivatives as janus kinase 2 inhibitors and uses thereof
CN109485620A (zh) * 2018-12-26 2019-03-19 安徽工大化工科技有限公司 一种2-甲氧基-6-甲氧基苯并噻唑的制备方法
MX2021009269A (es) * 2019-02-01 2021-08-24 Univ Leland Stanford Junior Inhibidores de enpp1 y metodos para modular una respuesta inmunitaria.
AU2020271855B2 (en) * 2019-04-12 2025-11-27 National Health Research Institutes Heterocyclic compounds as kinase inhibitors for therapeutic uses
CN111892536B (zh) * 2019-05-05 2022-06-28 北京福元医药股份有限公司 取代的喹啉甲酰胺类化合物及其用途
WO2020249096A1 (zh) * 2019-06-14 2020-12-17 南京明德新药研发有限公司 作为fgfr和vegfr双重抑制剂的并环类化合物
PL4010330T3 (pl) * 2019-08-08 2026-03-16 Hirundo Biosciences Pochodne chinoliny jako inhibitory kinazy białkowej
CA3156828A1 (en) 2019-10-03 2021-04-08 Dana-Farber Cancer Institute, Inc. Tricyclic kinase inhibitors and uses thereof
CN113321654B (zh) * 2020-02-28 2022-05-03 上海济煜医药科技有限公司 作为激酶抑制剂的稠合吡啶酮类化合物
TW202204350A (zh) 2020-05-06 2022-02-01 美商雅捷可斯治療公司 作為ｊａｋ２抑制劑之６－雜芳基氧基苯并咪唑及氮雜苯并咪唑
EP4267574B1 (en) 2020-12-23 2025-04-23 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors
CN113582924A (zh) * 2021-09-09 2021-11-02 四川国康药业有限公司 一种多靶点酪氨酸激酶抑制剂及其制备方法和用途
CA3234638A1 (en) 2021-11-09 2023-05-19 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors
US12162881B2 (en) 2021-11-09 2024-12-10 Ajax Therapeutics, Inc. Forms and compositions of inhibitors of JAK2
CN114213404B (zh) * 2021-12-27 2024-08-06 武汉九州钰民医药科技有限公司 Vegfr抑制剂替沃扎尼的合成工艺
WO2023185638A1 (zh) * 2022-03-29 2023-10-05 广东众生睿创生物科技有限公司 一种喹啉衍生物的晶型及其制备方法
CN115215799B (zh) * 2022-08-12 2024-05-31 上海爱博医药科技有限公司 脲类多靶点酪氨酸激酶抑制剂及其多种医药应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1252054C (zh) * 1996-09-25 2006-04-19 曾尼卡有限公司 抑制生长因子的作用的喹啉衍生物
GB9904103D0 (en) * 1999-02-24 1999-04-14 Zeneca Ltd Quinoline derivatives
WO2002012226A1 (en) * 2000-08-09 2002-02-14 Astrazeneca Ab Quinoline derivatives having vegf inhibiting activity
KR100600550B1 (ko) * 2000-10-20 2006-07-13 에자이 가부시키가이샤 질소 함유 방향환 유도체
WO2005021554A1 (en) * 2003-08-29 2005-03-10 Pfizer Inc. Thienopyridine-phenylacet amides and their derivatives useful as new anti-angiogenic agents
AP2006003619A0 (en) 2003-12-23 2006-06-30 Pfizer Novel quinoline derivatives
US7626030B2 (en) * 2004-01-23 2009-12-01 Amgen Inc. Compounds and methods of use
US20050288290A1 (en) 2004-06-28 2005-12-29 Borzilleri Robert M Fused heterocyclic kinase inhibitors
CN1993130B (zh) 2004-06-28 2010-06-23 布里斯托尔-迈尔斯斯奎布公司 用于制备稠合杂环激酶抑制剂的方法和中间体
WO2006125597A1 (en) * 2005-05-24 2006-11-30 Unilever N.V. Toothbrush
US20090247576A1 (en) * 2005-11-22 2009-10-01 Eisai R & D Management Co., Ltd. Anti-tumor agent for multiple myeloma
KR101464385B1 (ko) * 2006-04-19 2014-11-21 노파르티스 아게 ６-ｏ-치환된 벤즈옥사졸 및 벤조티아졸 화합물, 및 ｃｓｆ-１ｒ 신호전달의 억제 방법
JP4667537B2 (ja) * 2008-04-10 2011-04-13 大鵬薬品工業株式会社 アシルチオウレア化合物又はその塩、及びその用途
EP2550266B1 (en) * 2010-03-24 2018-05-09 Amitech Therapeutics Solutions, Inc. Heterocyclic compounds useful for kinase inhibition
CN102958523B (zh) * 2010-06-25 2014-11-19 卫材R&D管理有限公司 使用具有激酶抑制作用的组合的抗肿瘤剂
MX352844B (es) * 2011-02-28 2017-12-11 Calitor Sciences Llc Compuestos de quinolina sustituidos y metodos de uso.
CN102816175B (zh) * 2011-06-09 2015-12-16 上海汇伦生命科技有限公司 一种杂环并吡啶酮类化合物,其中间体、制备方法和用途
EA023521B1 (ru) * 2011-11-14 2016-06-30 Сефалон, Инк. ПРОИЗВОДНЫЕ УРАЦИЛА В КАЧЕСТВЕ ИНГИБИТОРОВ AXL И c-MET КИНАЗЫ
WO2013180949A1 (en) * 2012-05-27 2013-12-05 Ning Xi Substituted quinoline compounds and methods of use
JPWO2014098176A1 (ja) * 2012-12-21 2017-01-12 エーザイ・アール・アンド・ディー・マネジメント株式会社 キノリン誘導体のアモルファス及びその製造方法
CN106255499A (zh) * 2014-03-17 2016-12-21 埃克塞里艾克西斯公司 卡博替尼制剂的给药

Also Published As

Publication number Publication date
JP2018513150A (ja) 2018-05-24
CN107683279B (zh) 2020-11-03
CN112028825B (zh) 2025-03-14
CN112028825A (zh) 2020-12-04
EP3293177A4 (en) 2018-12-12
JP6617155B6 (ja) 2020-01-22
JP6617155B2 (ja) 2019-12-11
JP2020037576A (ja) 2020-03-12
JP6928774B2 (ja) 2021-09-01
EP3293177A1 (en) 2018-03-14
CN107683279A (zh) 2018-02-09
EP3293177B1 (en) 2024-11-27
WO2016161952A1 (zh) 2016-10-13
CN106046007A (zh) 2016-10-26
US20190119217A1 (en) 2019-04-25
US10654808B2 (en) 2020-05-19

Similar Documents

Publication Publication Date Title
CN107683279A (zh) 酪氨酸激酶抑制剂及包含该酪氨酸激酶抑制剂的药物组合物
JP7278649B2 (ja) Ｊａｋ阻害剤及びその製造方法
CN105085489B (zh) 嘧啶或吡啶类化合物、其制备方法和医药用途
HK1246294A1 (zh) 稠环或三环芳基嘧啶化合物用作激酶抑制剂
CN107428731A (zh) 作为抗癌药物的取代的2‑氢‑吡唑衍生物
CA2903463A1 (en) Bet bromodomain inhibitors and therapeutic methods using the same
CA2908098A1 (en) Mk2 inhibitors and uses thereof
CA2909310A1 (en) Quinazolines and azaquinazolines as dual inhibitors of ras/raf/mek/erk and pi3k/akt/pten/mtor pathways
CN107531695A (zh) Jak抑制剂
CN107922349A (zh) 作为fgfr和vegfr抑制剂的乙烯基化合物
CA2646166A1 (en) 3-substituted n-(aryl- or heteroaryl)-pyrazo[1,5-a]pyrimidines as kinase inhibitors
CN104341425A (zh) 氘代乙炔衍生物、其药物组合物及应用
WO2011041655A1 (en) Quinazolin-4-amine derivatives; and methods of use
Hao et al. Development of 2, 4-diaminoquinazoline derivatives as potent PAK4 inhibitors by the core refinement strategy
JP7190755B2 (ja) オキサジノキナゾリンおよびオキサジノキノリン系化合物、ならびに調製方法およびその使用
EP3712133B1 (en) Substituted benzimidazole compound and composition comprising same
CN104876934B (zh) 一种含氮杂环苯基哌啶类化合物及其制备方法与应用
CN106946896B (zh) 呋喃并[2,3-d]嘧啶-4-胺衍生物
CN116041341B (zh) 一种喹唑啉类par4拮抗剂及其医药应用
CN111018839A (zh) 三氮唑醇类衍生物及其制备方法和应用
CN105924403A (zh) 一种具有抗肿瘤活性的环丙二酰胺类化合物及其制备方法和应用
KR20250103668A (ko) 축합 이환 화합물
CN116969897A (zh) 一种磺酰胺类化合物及制备方法和应用、药物组合物
CN118063485A (zh) 新型取代噻吩并嘧啶类化合物及其制备方法和应用
CN114042069B (zh) 一种5-取代哒嗪-4-胺衍生物、制备方法和用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20181217

Address after: Room 1701-1705, Main Building, Rongyi Building, No. 5 Information Road, Songshan Lake Hi-tech Industrial Development Zone, Dongguan City, Guangdong Province

Applicant after: Guangdong Zhongsheng Ruichuang Biotechnology Co., Ltd.

Address before: 523325 Information Industry Park, Shilong Industrial Zone, Shilong Town, Dongguan, Guangdong, West Lake

Applicant before: Zhongsheng Pharmaceutical Co., Ltd., Guangdong

GR01 Patent grant
GR01 Patent grant